Immune checkpoint inhibitors for treatment of advanced stage melanoma
Immune checkpoint inhibitors for treatment of advanced stage melanoma. Immunotherapy, which stimulates the anti-tumor immune response, has significantly modified the prognosis of advanced stage melanoma. Anti-CTLA4 monoclonal antibody, ipilimumab, showed a benefit on survival compared to chemotherapy in 2011. Anti-PD1, nivolumab and pembrolizumab subsequently showed superior clinical benefit including overall survival and tolerance over anti-CTLA4. Currently, the combination of ipilimumab and nivolumab appears as the most effective immunotherapy but the toxicity of this regimen is a limitation. Anti-PD1 antibodies have also been evaluated in the adjuvant setting for patients with stage III or IV resected melanoma where they have shown a significant benefit in term of relapse-free-survival. Studies are underway to evaluate these drugs in stage II resected melanoma and in neo-adjuvant setting with promising results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
La Revue du praticien - 70(2020), 5 vom: 25. Mai, Seite 471-474 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Immunothérapie dans le traitement du mélanome au stade avancé |
|---|
| Beteiligte Personen: |
Lupu, Jeremy [VerfasserIn] |
|---|
| Themen: |
31YO63LBSN |
|---|
| Anmerkungen: |
Date Completed 19.10.2020 Date Revised 19.10.2020 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM316281697 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316281697 | ||
| 003 | DE-627 | ||
| 005 | 20231225160739.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||fre c | ||
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316281697 | ||
| 035 | |a (NLM)33058629 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Lupu, Jeremy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune checkpoint inhibitors for treatment of advanced stage melanoma |
| 246 | 3 | 3 | |a Immunothérapie dans le traitement du mélanome au stade avancé |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.10.2020 | ||
| 500 | |a Date Revised 19.10.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Immune checkpoint inhibitors for treatment of advanced stage melanoma. Immunotherapy, which stimulates the anti-tumor immune response, has significantly modified the prognosis of advanced stage melanoma. Anti-CTLA4 monoclonal antibody, ipilimumab, showed a benefit on survival compared to chemotherapy in 2011. Anti-PD1, nivolumab and pembrolizumab subsequently showed superior clinical benefit including overall survival and tolerance over anti-CTLA4. Currently, the combination of ipilimumab and nivolumab appears as the most effective immunotherapy but the toxicity of this regimen is a limitation. Anti-PD1 antibodies have also been evaluated in the adjuvant setting for patients with stage III or IV resected melanoma where they have shown a significant benefit in term of relapse-free-survival. Studies are underway to evaluate these drugs in stage II resected melanoma and in neo-adjuvant setting with promising results | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Melanoma | |
| 650 | 7 | |a Ipilimumab |2 NLM | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 700 | 1 | |a Herrscher, Hugo |e verfasserin |4 aut | |
| 700 | 1 | |a Robert, Caroline |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t La Revue du praticien |d 1951 |g 70(2020), 5 vom: 25. Mai, Seite 471-474 |w (DE-627)NLM000023248 |x 2101-017X |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2020 |g number:5 |g day:25 |g month:05 |g pages:471-474 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2020 |e 5 |b 25 |c 05 |h 471-474 | ||